ARTICLES|ONLINE FIRST Vaccine effectiveness against SARS-CoV-2 infection and severe outcomes among individuals with immune-mediated inflammatory diseases tested between March 1 and Nov 22, 2021, in Ontario, Canada: a population-based analysis Jessica Widdifield, Jeffrey C Kwong, Simon Chen, et al Lancet Rheumatol Published:April 14, 2022 DOI:https://doi.org/10.1016/S2665-9913(22)00096-0 Summary Background We estimated COVID-19 vaccine effectiveness ag...

CORRESPONDENCE Efficacy of a Fourth Dose of Covid-19 mRNA Vaccine against Omicron Gili Regev-Yochay, Tal Gonen, Mayan Gilboa, et al N Engl J Med March 16, 2022DOI: 10.1056/NEJMc2202542 TO THE EDITOR: In this open-label, nonrandomized clinical study, we assessed the immunogenicity and safety of a fourth dose of either BNT162b2 (Pfizer–BioNTech) or mRNA-1273 (Moderna) administered 4 months after the third dose in a series of three BNT162b2 doses (ClinicalTria...

ARTICLES|ONLINE FIRST Clinical features and management of human monkeypox: a retrospective observational study in the UK Hugh Adler, Susan Gould, Paul Hine, et al Lancet Infect Dis Published: May 24, 2022 DOI:https://doi.org/10.1016/S1473-3099(22)00228-6 Summary Background Cases of human monkeypox are rarely seen outside of west and central Africa. There are few data regarding viral kinetics or the duration of viral shedding and no licensed treatments...

ARTICLES| VOLUME 4, ISSUE 5, E351-E361, MAY 01, 2022 Ruxolitinib in addition to standard of care for the treatment of patients admitted to hospital with COVID-19 (RUXCOVID): a randomised, double-blind, placebo-controlled, phase 3 trial MeiLan K Han, Martti Antila, Joachim H Ficker, et al Lancet Rheumatol 2022; 4: e351-e361 Summary Background COVID-19 is associated with acute respiratory distress and cytokine release syndrome. The Janus kin...

ARTICLES| VOLUME 4, ISSUE 5, E338-E350, MAY 01, 2022 Humoral responses after second and third SARS-CoV-2 vaccination in patients with immune-mediated inflammatory disorders on immunosuppressants: a cohort study Luuk Wieske, Koos P J van Dam, Maurice Steenhuis, et al Lancet Rheumatol 2022; 4: e338-e350 Summary Background Disease-specific studies have reported impaired humoral responses after SARS-CoV-2 vaccination in patients with immune-me...

Original Investigation March 14, 2022 Effect of Sotrovimab on Hospitalization or Death Among High-risk Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial Anil Gupta, Yaneicy Gonzalez-Rojas, Erick Juarez, et al JAMA. Published online March 14, 2022. doi:10.1001/jama.2022.2832 Key Points Question  Among patients at risk of disease progression, does early treatment of mild to moderate COVID-19 with the neutralizing an...

Research Letter May 19, 2022 Severity and Incidence of Multisystem Inflammatory Syndrome in Children During 3 SARS-CoV-2 Pandemic Waves in Israel Nitai Levy, Jordanna H. Koppel, Or Kaplan, et al JAMA. Published online May 19, 2022. doi:10.1001/jama.2022.8025 Multisystem inflammatory syndrome in children (MIS-C) is a serious complication of SARS-CoV-2 infection.1 A previous study that described MIS-C cases in the first 3 waves of the COVID-19 pan...

ARTICLES|ONLINE FIRST Myopericarditis following COVID-19 vaccination and non-COVID-19 vaccination: a systematic review and meta-analysis Ryan Ruiyang Ling, Kollengode Ramanathan, Felicia Liying Tan, et al Lancet Respir Med Published:April 11, 2022 DOI:https://doi.org/10.1016/S2213-2600(22)00059-5 Summary Background Myopericarditis is a rare complication of vaccination. However, there have been increasing reports of myopericarditis following COVID-19 v...

CORRESPONDENCE|ONLINE FIRST Severe acute hepatitis in children: investigate SARS-CoV-2 superantigens Petter Brodin, Moshe Arditi Lancet Gastroenterol Hepatol Published: May 13, 2022 DOI: https://doi.org/10.1016/S2468-1253(22)00166-2 Recently, there have been reports of children with a severe acute form of hepatitis in the UK, Europe, the USA, Israel, and Japan.1 Most patients present with gastrointestinal symptoms and then progress to jaundice and, in ...

Research Letter February 3, 2022 Prevalence and Durability of SARS-CoV-2 Antibodies Among Unvaccinated US Adults by History of COVID-19 Jennifer L. Alejo, Jonathan Mitchell, Amy Chang, et al JAMA. 2022;327(11):1085-1087. doi:10.1001/jama.2022.1393 As of December 28, 2021, approximately 27% of the US population was unvaccinated against SARS-CoV-2,1 yet the prevalence of natural immunity remains unknown. Blood donor studies may have selection bias and lack ...